SCHEMBL2559376

SCHEMBL2559376

O=C(O)[C@@H]1CN[C@@H](C(=O)O)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 1.00
CYP1A2 P05177 2/20 1.00
ALOX15 P16050 2/20 1.00
CYP2C19 P33261 2/20 1.00
SLC1A3 P43003 1/20 1.00
SLC1A2 P43004 1/20 1.00
SLC1A1 P43005 1/20 1.00
TSHR P16473 3/20 0.48
LMNA P02545 2/20 0.48
BLM P54132 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
PMP22 Q01453 2/20 0.48
RAB9A P51151 1/20 0.48
THRB P10828 1/20 0.48
ARG1 P05089 1/20 0.46
KDM4E B2RXH2 1/20 0.39
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8480461 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL1133665 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL12648650 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL8480462 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL2808482 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL2484170 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL542244 1.00 CYP2D6 (1.00) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL17743411 0.98 CYP2D6 (0.95) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL21402235 0.98 CYP2D6 (0.95) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL6652332 0.86 CYP2D6 (0.75) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291301-B1 NON-INVASIVE CANCER TREATMENT SCIENTIA BIOTECH S L (ES) 2025-01-15 EP disclosed
EP-4291301-A1 NON-INVASIVE CANCER TREATMENT Scientia Biotech S.L. (ES) 2023-12-20 EP disclosed
EP-4277635-A1 MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME Yeda Research and Development Co. Ltd (IL) 2023-11-22 EP disclosed
WO-2022171826-A1 NON-INVASIVE CANCER TREATMENT SCIENTIA BIOTECH S.L (ES) 2022-08-18 WO disclosed
EP-4043071-A1 NON-INVASIVE CANCER TREATMENT Scientia Biotech S.L. (ES) 2022-08-17 EP disclosed
WO-2022153322-A1 MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2022-07-21 WO disclosed
EP-1397370-B1 BETA-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING SUNTORY HOLDINGS LTD (JP) 2014-07-23 EP disclosed
CN-103816168-A Application of acteoside in preparing medicine protecting cranial nerve cells damaged by ingestion and restraint of glutamate transporter XINJIANG UYGUR AUTONOMOUS REGION INST OF TRADITIONAL UYGUR MEDICINE 2014-05-28 CN disclosed
EP-2560687-A2 COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES Nlife Therapeutics S.L. (ES) 2013-02-27 EP disclosed
WO-2011131693-A2 COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES NLIFE THERAPEUTICS, S.L. (ES) 2011-10-27 WO disclosed
US-20040242652-A1 Beta benzyloxyaspartate derivatives with amino group on benzene ring SUNTORY HOLDINGS LTD. (JP) 2004-12-02 US disclosed
EP-1397370-A1 B-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING SUNTORY LIMITED (JP) 2004-03-17 EP disclosed
US-20030050224-A1 Blocking glutamate function at an ionotropic glutamate receptor. e.g., N-methyl-D-aspartate receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptor and the kainate receptor; brain disorders; spinal chord NEDERGAARD MAIKEN (US) 2003-03-13 US disclosed
WO-2003000698-A1 β-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING SUNTORY LIMITED (JP) 2003-01-03 WO disclosed
US-6090560-A SCREENING A COMPOUND FOR BINDING TO EXCITATORY AMINO ACID TRANSPORTER IN CELLS BY TRANSFORMING HOST CELL WITH RECOMBINANT EXPRESSION CONSTRUCT EXPRESSING HUMAN TRANSPORTER AND ASSAYING TO DETERMINE BINDING OREGON HEALTH SCIENCES UNIVERSITY (US) 2000-07-18 US disclosed
US-6060307-A Amino acid transporters and uses OREGON HEALTH SCIENCES UNIVERSITY (US) 2000-05-09 US disclosed
US-5942537-A ADMINISTERING A L-TRANS PYRROLIDINE DERIVATIVE TO INHIBIT THE TRANSPORT OF L-GLUTAMATE OR L-ASPARTATE OR AN EXCITATORY AMINO ACID NEUROTRANSMITTER AWAY FROM A SYNAPSE COMPRISING CONTACTING SYNAPSE WITH PYRROLIDINE DERIVATIVE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-08-24 US disclosed
US-5912171-A A NUCLEIC ACID WHICH CODES A MAMMALIAN EXCITATORY AMINO ACID GLUTAMATE TRANSPORTER PROTEIN; GENE THERAPY, DIAGNOSIS FOR HUNTINGTON'S/PARKISON'S/ALZHEIMER'S, DISEASES, EPILEPSY, ANOXIA AND ISCHEMIA OREGON HEALTH SCIENCE UNIVERSITY (US) 1999-06-15 US disclosed
EP-0497895-A1 METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1992-08-12 EP disclosed
WO-1991006536-A1 METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1991-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242652-A1 Beta benzyloxyaspartate derivatives with amino group on benzene ring SLC1A5, SLC1A1, SLC7A1 CYP2D6 2267/4885CYP1A2 3852/4885ALOX15 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.